Hablar con un orientador Llámenos +1 (800) 923-7404
TREATMENT GUIDE · OPTIONS TO EXPLORE

TULSA-PRO prostate ablation

Cancer treatment & testing

Prostate tissue ablation; long-term comparative outcomes under study

TULSA-PRO uses ultrasound delivered through the urethra to heat and destroy a planned volume of prostate tissue. MRI images and temperature measurements guide treatment; a separate cooling device helps protect the adjacent rectum. For cancer, assessment concerns selected localized prostate cases and the location, extent, and grade of disease. It is a procedure requiring specialist planning and anesthesia, rather than a medicine or general cancer-support therapy. [1, 2]

Information checked 2026-10-01 View sources ↓
A PLACE TO BEGIN

About this approach

TULSA-PRO uses ultrasound delivered through the urethra to heat and destroy a planned volume of prostate tissue. MRI images and temperature measurements guide treatment; a separate cooling device helps protect the adjacent rectum. For cancer, assessment concerns selected localized prostate cases and the location, extent, and grade of disease. It is a procedure requiring specialist planning and anesthesia, rather than a medicine or general cancer-support therapy. [1, 2]

Where it fits: Prostate tissue ablation; long-term comparative outcomes under study

CURRENT CLINICAL USE

Where this treatment is used

The FDA's September 2023 clearance, K230692, retains an indication for ultrasound ablation of prostate tissue through the urethra. This describes the device's permitted use; it does not by itself establish a cancer cure, a survival advantage, or superiority to surgery, radiation, or active surveillance. The original system was cleared in 2019. [1] The pivotal TACT study, published in the Journal of Urology in 2021, followed 115 men with localized, predominantly low- or intermediate-risk prostate cancer after whole-gland treatment. It was a prospective, single-arm study, without a randomized comparison group. At 12 months, 110 of 115 participants achieved the study's endpoint of at least a 75% PSA reduction. Among 111 men who had follow-up biopsy, 72 (65%) had no cancer detected. Whole-gland results also cannot simply be transferred to a focal treatment plan. [2] CAPTAIN, NCT05027477, is the randomized comparison with radical prostatectomy in localized intermediate-risk disease. Its primary outcomes include urinary and erectile function at 12 months and freedom from treatment failure at 36 months. The registry checked for this guide listed the study as active, not recruiting, with no posted results; its last posted update was August 17, 2025. Registry posting can lag conference reporting. [4] A 2026 ASCO conference abstract reported early comparative outcomes in 211 treated CAPTAIN participants: lower blood loss, shorter hospitalization, and less early pain with TULSA, but longer catheter use (median 13 versus 8 days). The primary functional and cancer-control outcomes were still pending.

WHAT TREATMENT MAY INVOLVE

Procedure and practical considerations

Reported adverse effects include urinary infection, blood in the urine, pain, difficulty passing urine, urethral narrowing, leakage, erectile difficulties, and changes in ejaculation. Some urinary or sexual effects persisted at the one-year assessment in the FDA's original clinical summary. Calling the approach minimally invasive does not mean recovery is immediate or complications cannot occur. [3] TACT reported severe, grade 3 adverse events in 9 of 115 men, and the median time to urinary catheter removal was 17 days; this is study experience, not a prediction for an individual. [2] Eligibility assessment also considers MRI and anesthesia suitability, prostate anatomy, obstructing calcifications, and infection. CAPTAIN's eligibility criteria illustrate these considerations but do not define every patient's suitability. Follow-up remains important: discuss a written plan for PSA testing, MRI, biopsy, symptom review, and the response if cancer remains or returns. CAPTAIN includes imaging, biopsy, and long-term outcome assessments. [4]

EXPLORE YOUR OPTIONS

Clinics reporting this approach

These clinic profiles connect to this approach through clinic-confirmed selections or Cancer Clinic Finder’s source review. Open a profile to compare locations, services, practical details, and ways to get started.

47 connected profiles

Browse all 47 connected profiles
FOLLOW THE INFORMATION

Sources

Source information checked: 2026-10-01. The links below identify the public and clinic-provided materials used for this page.

  1. FDA: K230692 clearance and TULSA-PRO device summary (2023), indication and treatment mechanism ↗Checked 2026-09-28
  2. Klotz et al., Journal of Urology (2021): pivotal TACT study, 12-month outcomes (PMID 33021440) ↗Checked 2026-09-28
  3. FDA: K191200 original TULSA-PRO clinical summary (2019), adverse events and functional effects ↗Checked 2026-09-28
  4. ClinicalTrials.gov: CAPTAIN randomized trial, NCT05027477; study design, eligibility, outcomes, and registry status ↗Checked 2026-09-28
  5. ASCO / Journal of Clinical Oncology (2026), abstract 369: early perioperative results from the randomized CAPTAIN trial ↗Checked 2026-09-28
  6. Profound Medical: public TULSA-PRO provider locator and listing limitations ↗Checked 2026-10-01

How Cancer Clinic Finder compiles information · Suggest a factual correction

SOLICITE UNA LLAMADA

Solicite una llamada.

Indíquenos el mejor número para localizarle. Un orientador le llamará para ayudarle a explorar centros de tratamiento.

Esta solicitud llega a nuestro equipo, no a una clínica. No incluya expedientes médicos ni información médica confidencial.

+1 800 923 7404 Qué sucede durante la llamada ↗